JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Corvus Pharmaceuticals Inc

Closed

7.16 -0.28

Overview

Share price change

24h

Current

Min

7.01

Max

7.35

Key metrics

By Trading Economics

Income

-23M

-8M

Profit margin

-13,764.773

Employees

31

EBITDA

-360K

-10M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+94.99% upside

Dividends

By Dow Jones

Next Earnings

12 Nov 2025

Market Stats

By TradingEconomics

Market Cap

224M

557M

Previous open

7.44

Previous close

7.16

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Corvus Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

23 Oct 2025, 20:49 UTC

Earnings

Correction to Thermo Fisher Article on Oct. 22

23 Oct 2025, 23:51 UTC

Market Talk

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 Oct 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 Oct 2025, 23:49 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 Oct 2025, 23:37 UTC

Market Talk

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 Oct 2025, 22:58 UTC

Market Talk

Global Energy Roundup: Market Talk

23 Oct 2025, 22:57 UTC

Market Talk

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 Oct 2025, 22:49 UTC

Acquisitions, Mergers, Takeovers

How Trump Sparked a New Era of State Capitalism -2-

23 Oct 2025, 22:49 UTC

Acquisitions, Mergers, Takeovers

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 Oct 2025, 22:17 UTC

Earnings

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 Oct 2025, 21:41 UTC

Earnings

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 Oct 2025, 21:05 UTC

Earnings

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 Oct 2025, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

23 Oct 2025, 20:50 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

23 Oct 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23 Oct 2025, 20:35 UTC

Earnings

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 Oct 2025, 20:28 UTC

Earnings

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 Oct 2025, 20:15 UTC

Market Talk
Earnings

Global Commodities Roundup: Market Talk

23 Oct 2025, 20:10 UTC

Earnings

Newmont Mining 3Q Adj EPS $1.71

23 Oct 2025, 20:10 UTC

Earnings

Newmont Mining 3Q Sales $5.52B

23 Oct 2025, 20:10 UTC

Earnings

Newmont Mining 3Q EPS $1.67

23 Oct 2025, 20:09 UTC

Earnings

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 Oct 2025, 20:07 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

23 Oct 2025, 20:07 UTC

Market Talk
Earnings

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 Oct 2025, 20:07 UTC

Earnings

Blackstone Looks to IPOs for Investment Exits -- Update

23 Oct 2025, 20:05 UTC

Earnings

Intel 3Q Gross Margin 38.2% >INTC

23 Oct 2025, 20:04 UTC

Earnings

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 Oct 2025, 20:04 UTC

Earnings

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 Oct 2025, 20:04 UTC

Earnings

Intel: 4Q Guidance Excludes Altera >INTC

23 Oct 2025, 20:04 UTC

Earnings

Intel Sees 4Q Adj EPS 8c >INTC

Peer Comparison

Price change

Corvus Pharmaceuticals Inc Forecast

Price Target

By TipRanks

94.99% upside

12 Months Forecast

Average 14 USD  94.99%

High 16 USD

Low 11 USD

Based on 3 Wall Street analysts offering 12 month price targets forCorvus Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

3.165 / 3.5827Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat